Retatrutide and tirzepatide are built on the same GIP-based, 39-residue architecture and the same acylation strategy; the difference that matters is the third receptor. Tirzepatide engages the GIP and GLP-1 receptors. Retatrutide adds glucagon receptor agonism, making it a triple agonist. In a retatrutide vs tirzepatide comparison, that added glucagon arm is not a marginal upgrade — it introduces an energy-expenditure and hepatic-substrate component that incretin agonism alone does not produce, and it makes every readout harder to attribute without the right control arms.
Both are stocked as lyophilized powder in sealed vials with lot-matched HPLC certificates: retatrutide in 10, 20, 30, 48 and 60 mg sizes and tirzepatide in 10, 20, 30, 60 and 100 mg sizes, both within the GLP-1 and incretin peptides range. Both are supplied for laboratory research use only. Where human trial data are mentioned below, they describe investigational or approved pharmaceutical products studied under medical supervision, not the research-grade material sold here.
Retatrutide vs tirzepatide at a glance
| Attribute | Retatrutide | Tirzepatide |
|---|---|---|
| Class | Acylated triple GIP / GLP-1 / glucagon receptor agonist | Acylated dual GIP / GLP-1 receptor agonist |
| Receptors engaged | GIP, GLP-1 and glucagon receptors | GIP and GLP-1 receptors |
| Backbone | GIP-based, 39 residues | GIP-based, 39 residues |
| CAS number | 2381089-83-2 | 2023788-19-2 |
| Molecular formula | C221H342N46O68 | C225H348N48O68 |
| Molecular weight | 4731.30 g/mol | 4813.45 g/mol |
| Key modifications | Aib residues, alpha-Me-Leu, Lys-linked (AEEA)-gamma-Glu-C20 diacid, C-terminal serinamide | Aib residues, Lys20-linked gamma-Glu-(AEEA)2-C20 diacid, C-terminal amide |
| Distinctive pharmacology | Glucagon receptor arm adds hepatic and energy-expenditure endpoints | GIP-weighted potency with reported signaling bias at the GLP-1 receptor |
| Reported half-life (clinical-grade product, human PK) | Approximately six days | Approximately five days |
| Typical research question | Multi-receptor metabolic signaling, energy expenditure, hepatic lipid handling | Incretin receptor crosstalk, insulin secretion, adipose and energy-balance models |
| Control arms usually required | Dual agonist plus mono-agonist, or glucagon receptor antagonist | Mono-agonist, or GIP receptor antagonist / knockout |
| Research sizes stocked | 10, 20, 30, 48, 60 mg | 10, 20, 30, 60, 100 mg |
| Purity | ≥99% HPLC, lot-matched COA | ≥99% HPLC, lot-matched COA |
Structure: same family, one extra receptor
Both peptides start from a glucose-dependent insulinotropic polypeptide scaffold of 39 residues and both use the now-standard persistence strategy: alpha-aminoisobutyric acid substitutions to resist dipeptidyl peptidase-4 cleavage, plus a lysine-linked gamma-glutamyl/AEEA spacer carrying a C20 fatty diacid for reversible albumin binding. The molecular weights sit within about 80 g/mol of each other, and the formulas differ by only a handful of atoms.
Retatrutide's departures are concentrated where receptor selectivity is decided. It carries an alpha-methyl-leucine substitution alongside its Aib residues and terminates in a serinamide rather than a simple amide. The functional consequence is glucagon receptor engagement layered onto incretin agonism — a design that traces back to the older oxyntomodulin literature, where a single proglucagon-derived peptide naturally hits both the GLP-1 and glucagon receptors. Retatrutide is the engineered version of that idea with GIP activity added. For the full structural write-up see what is retatrutide.
Receptor pharmacology: what the third arm changes
Tirzepatide's published characterisation describes an imbalanced dual profile: potency at the GIP receptor closer to that of native GIP than its GLP-1 receptor potency is to native GLP-1, with signaling bias at the GLP-1 receptor toward cyclic-AMP accumulation over beta-arrestin recruitment and comparatively little receptor internalisation. Experiments with it usually ask how two incretin signals combine.
Retatrutide is characterised as a balanced-to-glucagon-weighted triple agonist, and its glucagon receptor arm is what investigators are usually after. Glucagon receptor agonism has a long preclinical literature of its own: hepatic glycogenolysis and gluconeogenesis, hepatic lipid oxidation, and increased energy expenditure measured by indirect calorimetry. Pairing that with incretin-driven intake suppression is a deliberate attempt to combine an intake arm with an expenditure arm in one molecule. It is also why retatrutide readouts are harder to interpret: an effect on hepatic triglyceride content or oxygen consumption could originate from any of three receptors, and separating them requires either receptor-selective antagonists, knockout tissue, or a parallel dual-agonist arm — which is precisely the role tirzepatide plays in many published designs.
Ranked control-arm design
- Establish potency at each receptor separately in transfected cell lines, reported in molar units, before moving to tissue.
- Run a dual-agonist comparator (tirzepatide) at matched receptor occupancy, not matched mass.
- Add a glucagon receptor antagonist or a glucagon-receptor-deficient arm where the endpoint is hepatic or calorimetric.
- Include a GLP-1 mono-agonist such as semaglutide where intake suppression is the readout, since that arm is shared by all three molecules.
What the research literature has examined
For tirzepatide, published preclinical work concentrates on incretin receptor crosstalk — comparative cyclic-AMP potency panels, beta-arrestin and internalisation assays, islet insulin-secretion studies and rodent energy-balance models. The complication acknowledged throughout that literature is that both GIP receptor agonism and GIP receptor antagonism have been reported to produce metabolic effects in animal models, so a positive result with a GIP-containing molecule does not by itself settle the direction of GIP's contribution.
For retatrutide, the distinctive published work is the glucagon-arm question: whether adding glucagon receptor agonism increases energy expenditure in rodent models, how it alters hepatic lipid content and ketone production, and whether the hepatic effects seen preclinically are separable from intake suppression. Human trial data for the clinical-grade investigational product have been reported in the metabolic literature and summarised in our 2026 retatrutide data update; those results describe a supervised clinical article, not research material. Both molecules appear as reference tools rather than endpoints in the wider weight-loss peptide research overview.
Which to select for which research question
- Incretin crosstalk without a glucagon confound — tirzepatide. Two receptors are already hard enough to deconvolve; three is harder.
- Energy expenditure, indirect calorimetry, hepatic lipid or ketone endpoints — retatrutide, because the glucagon arm is what generates those signals.
- Head-to-head potency benchmarking of a novel multi-agonist — both, run in the same panel so the new molecule can be positioned between a dual and a triple agonist.
- Hepatocyte and liver-model work — retatrutide, with a glucagon receptor control arm, since hepatic substrate handling is where the glucagon signal is most visible.
- Islet and beta-cell secretion studies — tirzepatide is the more conventional starting point, since glucagon receptor activity introduces an alpha-cell dimension.
- Amylin combination work — neither alone; the paired formats such as retatrutide with cagrilintide exist for that comparison.
Handling and storage differences
Handling is nearly identical, which is unsurprising given the shared scaffold. Both are lyophilized powders that reconstitute in bacteriostatic water and dissolve in dilute alkaline or phosphate buffers where assay pH matters; both are held at −20 °C lyophilized, sealed and protected from light and moisture, and at 2–8 °C once in solution, protected from light and used within the study window. General principles are covered in how to store peptides.
Two practical notes. Both carry a C20 diacid, so both are more lipophilic than a GLP-1 mono-agonist and both benefit from low-binding tubes, gentle swirling instead of vortexing, and visual inspection of concentrated stocks for haze before use. And because the two molecular weights are close but not equal, a matched-mass comparison is off by roughly 2% in molar terms — small, but it compounds across a serial dilution, so build the series in molar units using the figures above and the method in molecular weight, moles and molarity.
Purity, identity and why the COA matters more here
Multi-agonist peptides of 39 residues with acyl side chains are synthetically demanding, and the failure modes are specific: incomplete acylation, deletion sequences and partial loss of the C-terminal amide or serinamide. Each of those shifts the mass in a predictable direction, which is why the mass-spectrometric result on a lot-matched certificate of analysis is the fastest identity check available — 4731.30 g/mol for retatrutide and 4813.45 g/mol for tirzepatide. Read the HPLC trace for the size and position of secondary peaks rather than only the headline percentage; how to read a peptide COA covers the interpretation. Because the two molecules sit only 82 g/mol apart, a low-resolution mass result is not sufficient to distinguish them, so confirm the lot number on the vial matches the certificate.
Regulatory framing
Retatrutide and tirzepatide are supplied for laboratory research use only and are not medicines, foods or veterinary products. Tirzepatide is the active molecule in approved prescription pharmaceuticals; retatrutide has been studied as an investigational agent. In both cases the clinical evidence attaches to those regulated articles and to the supervised settings in which they were studied, and it should be cited as such rather than as evidence about research-grade peptide.